Key facts
- Hillstar Bio’s last known valuation is $105.0M (Mar 2025).
- It has raised $66.5M; the latest was Early Stage VC ($66.5M) in Mar 2025.
- Notable investors include Novo Holdings, Frazier Healthcare Partners, Droia Ventures, Hummingbird Bioscience, LifeArc Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Hillstar Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Hillstar Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hillstar Bio
Developer of autoimmune drugs intended to address unmet medical needs. The company's technique selectively targets and depletes pathogenic immune cells while sparing healthy ones, which addresses specific disease mechanisms by eliminating the underlying source and reducing the risks associated with chronic broad immunosuppression, enabling clients to offer the potential for durable relief and immune reset for patients with autoimmune conditions.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2023
- Employees
- 23
- Website
- hillstarbio.com/
- Ownership
- Privately Held (backing)
Hillstar Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hillstar Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hillstar Bio in its N-PORT filings yet. We sweep new filings monthly.